Cataract – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Cataract – Drugs In Development, 2024 report and make more profitable business decisions.
A cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred, or dim vision; increasing difficulty with vision at night; fading or yellowing of colors; double vision in a single eye; and frequent prescription changes in eye wear. Risk factors include age, diabetes, excessive alcohol consumption, high blood pressure, obesity, and smoking.
The Cataract drugs in development market research report provide comprehensive information on the therapeutics under development for Cataract, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cataract and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Cataract | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 20 molecules, with 18 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Cataract therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Cataract pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Cataract treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Calpain Therapeutics Pty LtdCaregen Co Ltd
CGeneTech (Suzhou China) Co Ltd
Emmecell LLC
Genisphere LLC
Kubota Vision Inc
Medispan
Nacuity Pharmaceuticals Inc
New York University
Optus Pharmaceutical Co Ltd
Plex Pharmaceuticals Inc
PromiSight Inc
TelomEye Pharmaceuticals Corp
Theialife Sciences Pvt Ltd
Visus Therapeutics Inc
Vitreo Pharma Inc
Zhejiang Raytone Biotechnology Co Ltd
Zhongshan Ophthalmic Center
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Cataract reports